7Baggers
The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.

SpringWorks Therapeutics, Inc
(NASDAQ:SWTX) 

SWTX stock logo

SpringWorks Therapeutics, Inc., a clinical-stage biopharmaceutical company, acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that ...

Founded: 2017
Full Time Employees: 71
CEO: Saqib Islam  
Sector: Healthcare
Industry: Biotechnology
Pharmaceuticals
Share this website to your friends
SpringWorks Therapeutics Days Payable Outstanding ttm (DPO)
202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 0167.31334.62501.93669.24836.551,003.861,171.17
SpringWorks Therapeutics Days Receivable Outstanding ttm (DSO)
202209 202210 202211 202212 202301 202302 202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 013.7927.5941.3855.1768.9682.7696.55
SpringWorks Therapeutics Days Inventory Outstanding ttm (DIO)
202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 070.19140.39210.58280.78350.97421.17491.36
SpringWorks Therapeutics Op Cashflow Per Share ttm
202209 202210 202211 202212 202301 202302 202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 -3.57-3.06-2.55-2.04-1.53-1.02-0.510
SpringWorks Therapeutics Free Cashflow Per Share ttm
202209 202210 202211 202212 202301 202302 202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 -3.72-3.19-2.66-2.13-1.6-1.06-0.53-0
SpringWorks Therapeutics Cash Per Share ttm
202209 202210 202211 202212 202301 202302 202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 01.763.525.287.048.810.5612.32
SpringWorks Therapeutics P/S ratio ttm
202209 202210 202211 202212 202301 202302 202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 016.7533.5150.2667.0283.77100.53117.28Thousand
SpringWorks Therapeutics (GAAP) P/E ratio ttm
202209 202210 202211 202212 202301 202302 202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 -5,500.5-4,714.72-3,928.93-3,143.15-2,357.36-1,571.57-785.790
SpringWorks Therapeutics P/B ratio ttm
202209 202210 202211 202212 202301 202302 202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 0502.071,004.141,506.212,008.282,510.353,012.433,514.5
No extra charts and metrics for this ticker.